Show simple item record

dc.contributor.authorNelson, L.M.
dc.contributor.authorWallin, M.T.
dc.contributor.authorMarrie, R.A.
dc.date.accessioned2019-09-13T14:49:27Z
dc.date.available2019-09-13T14:49:27Z
dc.date.issued2019
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85062387063&doi=10.1212%2fWNL.0000000000007044&partnerID=40&md5=d958e3e2895acab63fc8a98870e3427e
dc.identifier.urihttp://hdl.handle.net/10713/10535
dc.description.abstractConsiderable gaps exist in knowledge regarding the prevalence of neurologic diseases, such as multiple sclerosis (MS), in the United States. Therefore, the MS Prevalence Working Group sought to review and evaluate alternative methods for obtaining a scientifically valid estimate of national MS prevalence in the current health care era.MethodsWe carried out a strengths, weaknesses, opportunities, and threats (SWOT) analysis for 3 approaches to estimate MS prevalence: population-based MS registries, national probability health surveys, and analysis of administrative health claims databases. We reviewed MS prevalence studies conducted in the United States and critically examined possible methods for estimating national MS prevalence.ResultsWe developed a new 4-step approach for estimating MS prevalence in the United States. First, identify administrative health claim databases covering publicly and privately insured populations in the United States. Second, develop and validate a highly accurate MS case-finding algorithm that can be standardly applied in all databases. Third, apply a case definition algorithm to estimate MS prevalence in each population. Fourth, combine MS prevalence estimates into a single estimate of US prevalence, weighted according to the number of insured persons in each health insurance segment.ConclusionsBy addressing methodologic challenges and proposing a new approach for measuring the prevalence of MS in the United States, we hope that our work will benefit scientists who study neurologic and other chronic conditions for which national prevalence estimates do not exist. Copyright 2019 American Academy of Neurology.en_US
dc.description.urihttps://doi.org/10.1212/WNL.0000000000007044en_US
dc.language.isoen-USen_US
dc.publisherLippincott Williams and Wilkinsen_US
dc.relation.ispartofNeurology
dc.subject.meshMultiple Sclerosisen_US
dc.subject.meshUnited Statesen_US
dc.titleA new way to estimate neurologic disease prevalence in the United States: Illustrated with MSen_US
dc.typeArticleen_US
dc.identifier.doi10.1212/WNL.0000000000007044
dc.identifier.pmid30770422


This item appears in the following Collection(s)

Show simple item record